CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-10-03 | Katkin Keith Director | Option exercise | +13 | $8.93 | $116 | 32,013 |
| 2022-10-03 | Katkin Keith Director | Sale | −13 | $25.00 | $325 | 32,000 |
| 2022-10-03 | Katkin Keith Director | Option exercise · Stock Options (Right to buy) | −13 | 0 | ||
| 2022-10-03 | Katkin Keith Director | Option exercise · Stock Options (Right to buy) | −167 | 0 | ||
| 2022-09-30 | Metzger Michael A Chief Executive Officer | Option exercise | +29,606 | $8.77 | $260K | 47,265 |
| 2022-09-30 | Metzger Michael A Chief Executive Officer | Sale | −29,606 | $25.02 | $741K | 17,659 |
| 2022-09-30 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −29,606 | 0 | ||
| 2022-09-30 | Katkin Keith Director | Option exercise | +2,914 | $7.88 | $23K | 34,914 |
| 2022-09-30 | Katkin Keith Director | Sale | −2,914 | $25.07 | $73K | 32,000 |
| 2022-09-30 | Katkin Keith Director | Option exercise | +647 | $8.93 | $6K | 32,647 |
| 2022-09-30 | Katkin Keith Director | Sale | −647 | $25.07 | $16K | 32,000 |
| 2022-09-30 | Katkin Keith Director | Option exercise · Stock Options (Right to buy) | −647 | 0 | ||
| 2022-09-30 | Katkin Keith Director | Option exercise · Stock Options (Right to buy) | −2,914 | 0 | ||
| 2022-09-20 | Morrison Briggs President, Head of R&D | Option exercise | +59,649 | $10.90 | $650K | 77,485 |
| 2022-09-20 | Morrison Briggs President, Head of R&D | Sale | −59,649 | $23.25 | $1.4M | 17,836 |
| 2022-09-20 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −59,649 | 0 | ||
| 2022-09-19 | Morrison Briggs President, Head of R&D | Option exercise | +114,339 | $10.90 | $1.2M | 132,175 |
| 2022-09-19 | Morrison Briggs President, Head of R&D | Sale | −114,339 | $23.03 | $2.6M | 17,836 |
| 2022-09-19 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −114,339 | 0 | ||
| 2022-09-16 | Morrison Briggs President, Head of R&D | Option exercise | +71,966 | $7.20 | $518K | 89,802 |
Page 11 of 15 · 290 trades